ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-16

Price

$115.10

+0.09%

Score15.5Priority

Signals6/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.4xvs 20d avg

Analysis

The price action in Arcellx (ACLX) is entirely driven by Gilead Sciences' definitive agreement to acquire the company for $115 per share in cash plus a $5 Contingent Value Right (CVR). This M&A catalyst perfectly explains the QUIET_STORM technical signal, as the stock's exceptionally low 1.9% realized volatility reflects a classic merger arbitrage peg. While the broader market is in a RISK_ON regime with institutional investors shrugging off geopolitical threats, ACLX is structurally insulated from these macro crosscurrents. High conviction is warranted here because the stock's current price of $115.10 indicates zero financing or regulatory stress, confidently pricing in the $115 cash deal with a fractional premium for the CVR.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUEWEAK FINISH

Key Takeaways

Thestockistradingasapuremergerarbitragevehicle, peggedtoGilead's$115/sharecashofferwithaslight$0.10premiumreflectingthemarket'spricingofthe$5CVR[1.6].
Technical signals like SURGE and ALPHA_MALE captured the initial buyout gap, while QUIET_STORM and plummeting volatility (1.9% annualized) confirm institutional absorption and an absence of liquidity stress.
Macro risks and geopolitical noise are irrelevant; the core risk is regulatory intervention (FTC) or a failure to close the tender offer.

← Back to 2026-04-16 View Full ACLX History →Yahoo Finance &nearr;